DCGI green flag to Abbott heart failure, angina treatment drug Ivabradine
Abbott plans to launch Ivabradine prolonged-release tablets in the Indian market in the coming weeks.
New Delhi: Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for the treatment of chronic heart failure and chronic stable angina.
The company plans to launch Ivabradine prolonged-release tablets in the Indian market in the coming weeks, Abbott said in a statement.
This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added.
The formulation has been developed at Abbott's innovation & development (I&D) center in Mumbai, the statement said.
Also Read: Abbott Rapid Covid-19 Test Kit Gets USFDA Nod For Emergency Use
"Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said.
The convenient once-a-day formulation will help improve overall treatment adherence, leading to better health outcomes, he added.
Also Read: Abbott Sees No Hit To Demand For COVID-19 Tests From Vaccine
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.